Therapeutic Potential of Marine Probiotics: A Survey on the Anticancer and Antibacterial Effects of Pseudoalteromonas spp.

Abstract

Due to the increasing limitations and negative impacts of the current options for preventing and managing diseases, including chemotherapeutic drugs and radiation, alternative therapies are needed, especially ones utilizing and maximizing natural products (NPs). NPs abound with diverse bioactive primary and secondary metabolites and compounds with therapeutic properties. Marine probiotics are beneficial microorganisms that inhabit marine environments and can benefit their hosts by improving health, growth, and disease resistance. Several studies have shown they possess potential bioactive and therapeutic actions against diverse disease conditions, thus opening the way for possible exploitation of their benefits through their application. Pseudoalteromonas spp. are a widely distributed heterotrophic, flagellated, non-spore-forming, rod-shaped, and gram-negative marine probiotic bacteria species with reported therapeutic capabilities, including anti-cancer and -bacterial effects. This review discusses the basic concepts of marine probiotics and their therapeutic effects. Additionally, a survey of the anticancer and antibacterial effects of Pseudoalteromonas spp. is presented. Finally, marine probiotic production, advances, prospects, and future perspectives is presented.

High-throughput analysis using 16S rRNA sequencing of bacterial communities associated in selected mangrove species from Bayug Island, Iligan City, Philippines

“…Microorganisms found in mangroves are not only beneficial to the plants themselves because some species, like those from the genus Pseudoalteromonas, exhibit pharmaceutically relevant activities that can be harnessed for medicinal purposes (Offret et al 2016;Eze et al 2023). According to Srinivasan et al (2021), Pseudoalteromonas spp.…”

Genome‐based taxonomic analysis of the genus Pseudoalteromonas reveals heterotypic synonyms

“…Pigmented strains tend to have larger genomes and are more common producers of natural products; up to 15% of some Pseudoalteromonas genomes encode secondary metabolite gene clusters (Bowman, 2007;Egan et al, 2002;Paulsen et al, 2019;Vynne et al, 2011). Antimicrobial compounds produced by this genus are primarily alkaloids (both halogenated and non-halogenated), polyketides, and peptides, which encompass non-ribosomal and ribosomally derived peptides, with a broad spectrum of activities (Eze et al, 2023;Offret et al, 2016).…”

“…As taxonomy is a fundamental scientific endeavour, and the specific nomenclature of species has far-reaching influence and consequences in medical, government, regulatory, and industrial situations, it is necessary to maintain updated and accurate taxonomic records (Garrity & Lyons, 2003). This is especially relevant for the Pseudoalteromonas genus due to the many members that produce compounds and activities with potential use in pharmaceutical and industrial processes (Bowman, 2007;Eze et al, 2023); nomenclature of the producing organism(s) is paramount in successful regulatory submissions to register products. Additionally, accurate nomenclature is necessary for determinations of environmental prevalence and ecology, niche specialization, and metagenomic studies that attribute genomic components to species based on sequence comparison.…”